Across TCGA pan-cancer cohorts, AP1S1 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated AP1S1 data layer compared with 28 for mass-spec protein and 7 for mass-spec protein.
The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher AP1S1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated AP1S1 expression acts as an unfavorable survival marker.
KIRP are the cancer types where AP1S1 Mutation most reproducibly stratifies survival.